low - As a pre-revenue clinical-stage company, Anteris is insulated from economic cycles affecting device sales. However, hospital capital budgets for new technology adoption post-approval could face pressure in recessions. Primary sensitivity is to biotech funding cycles and risk appetite for clinical-stage assets rather than GDP growth.

Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (estimated commercialization 2027-2028). Clinical-stage medtech trades at 8-12x forward revenue multiples, highly sensitive to risk-free rate changes. Higher rates also increase cost of capital for future financing rounds, potentially forcing more dilutive equity raises. Debt financing unavailable at this stage given negative cash flow.

growth/speculative - Attracts high-risk biotech investors seeking asymmetric returns from successful clinical development and regulatory approval. 65% three-month return suggests momentum traders active on clinical milestones. Negative margins and pre-revenue status eliminate value and income investors. Requires 3-5 year investment horizon and tolerance for binary outcomes and significant dilution risk. Typical holders include specialized healthcare funds, Australian biotech investors, and retail speculators.